We discuss inference for a human phage display experiment with three stages. The data are tripeptide counts by tissue and stage. The primary aim of the experiment is to identify ligands that bind with high affinity to a given tissue. We formalize the research question as inference about the monotonicity of mean counts over stages. The inference goal is then to identify a list of peptidetissue pairs with significant increase over stages. We use a semi-parametric Dirichlet process mixture of Poisson model. The posterior distribution under this model allows the desired inference about the monotonicity of mean counts. However, the desired inference summary as a list of peptide-tissue pairs with significant increase involves a massive multiplicity problem. We consider two alternative approaches to address this multiplicity issue. First we propose an approach based on the control of the posterior expected false discovery rate. We notice that the implied solution ignores the relative size of the increase. This motivates a second approach based on a utility function that includes explicit weights for the size of the increase.
Introduction
We develop semi-parametric Bayesian inference for data from a human phage display experiment. The experiment is carried out to learn about preferential binding of proteins in certain tissues. The long-term goal is to exploit such knowledge to develop targeted therapies that could deliver a drug to specific tissues and limit side effects such as toxicity (Kolonin et. al., 2006; Arap et al., 2006) . For example, our previous collaborative work identified the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer (Arap et. al., 2002 and Zurita AJ, et. al., 2004) and served as the basis for an ongoing first-in-man trial. It was identified starting from some of the most amplified protein-tissue pairs in similar phage display experiments. A phage library is a collection of millions to billions of random peptides displayed on filamentous bacteriophage within the pIII capsid protein (Pasqualini, 2000) . Bacteriophages, for short phages, are viruses that parasite only bacteria. Phages are one of the most common and diverse biological organisms in the biosphere. They provide a convenient mechanism to study the preferential binding of peptides to tissues. In an in vivo phage display experiment an unselected phage display library is administered by intravenous infusion, and 15 minutes later, tissue biopsies are obtained to recover phage from different tissues (Arap et. al., 2002) . Kolonin et. al. (2006) proposed a multistage phage display experiment, that is, successive stages of screening (usually three or four) to enrich and amplify tissue specific peptides in parallel. This procedure allows for the counts of peptides to increase in every stage and, therefore, it increases the chance of detecting their selection behavior. Kolonin et. al. (2006) use a three step procedure to identify preferentially binding peptidetissue pairs. In a first step they use a Bayesian beta-binomial model to make a list of the peptide-tissue pairs with relatively large increases from the first to the third stages. The second and third step implement (frequentist) tests in contingency tables comparing counts for each peptide A and tissue T versus non-A and non-T. See the more detailed discussion later, in Subsection 3.1. Any peptide A that passes all three filters is reported as binding with preferential selection to tissue T. Ji et. al. (2007) proposed a Bayesian hierarchical model as a way of accounting for correlation between measurements and reducing the number of parameters. They used a false discovery rate (FDR) criterion (see Newton, 2004) to report high-binding peptides for a 3-stage phage display experiment with mouse data. Later, in Section 3, we argue that this parametric hierarchical model is inappropriate for the human data described below. Taking advantage of the large sample size of this data set, we propose instead a semi-parametric Bayesian model that avoids some of the limitations of the fully parametric model described by Ji et. al .Also, we propose an alternative criterion to select high-binding peptides based on a decision theoretic framework. The proposed model and decision theoretic solution addresses multiplicity issues in several ways. First, a hierarchical model adjusts the posterior probabilities for multiplicities. This is discussed, for example, in Scott and Berger (2010) .
Second, inference under the particular non-parametric Bayesian model can be interpreted as a Bayesian version of Storey's (2007) optimal discovery procedure (Guindani et al. 2009 ).
Third, the use of a problem-specific utility function leads us to use a slight variation of traditional rules. Instead of thresholding p-values or marginal posterior probabilities we threshold marginal posterior mean effects.
The main contributions of this paper are the use of a non-parametric prior to avoid the limitations of specific parametric assumptions, and the use of a decision theoretic framework to address the multiplicity issues arising in the selection of a list of tripeptides-tissue pairs that are reported for significant affinity. The remainder of this paper is organized as follows.
Section 2 presents a detailed description of the multistage human data. We propose a Bayesian semi-parametric mixture of Poisson model and briefly describe the Markov Chain Monte Carlo (MCMC) simulation scheme for obtaining random samples of the posterior distribution in Section 3. In Section 4, we discuss the criterion to select the peptides that bind specific to certain tissues. In Section 5, we perform a simulation study to asses further the properties of our model and our peptide selecting criterion. In Section 6, we show the results of applying our model to the human 3-stage screening experiment. Finally, we provide some concluding remarks in Section 7.
Data
The data are from cancer patients at M. D. Anderson Cancer Center. The data come from three consecutive human subjects who met the formal criteria for brain-based determination of death (Wijdicks, 2001) . See Arap et. al. (2002) for details of the patient selection and the clinical procedure following strict criteria of clinical ethics. One of the primary goals of the study (Staquicini et. al., 2011) is to identify peptides with increasing trend over the consecutive stages. Figure 1 shows a schematic representation of the experiment. The bacteriophages that are injected in each of the stages, i.e., in each of the three human subjects, provide a convenient mechanism to study the preferential binding of peptides to tissues. In summary, the setup is a 3-stage biopanning experiment with bacteriophages delivering random peptides to tissues and the multiple stages allowing for an augmented and easier to detect signal.
[ Figure 1 about here.]
At each stage we record counts for peptide-tissue pairs. Peptides are denoted as CX 7 C (here C =cysteine, X = any amino acid, represented by a letter). Tissues included in this study are bone-marrow (BM), fat (F), muscle (MU), prostate (PR) and skin (SK). At each stage a phage display peptide library was injected into a new patient, and 15 minutes later biopsies were collected from each of the target tissues and the phage inserts were sequenced.
For the second and third stage the input was the pooled inserts amplified from the previous stage.
The original data are counts for all unique 7-mers X 7 . However, we summarize the data using all implied 3-mers. For example, the 7-mer AGAGADR corresponds to the four unique tripeptides AGA,GAG,DAG and ADR. Note that we do not distinguish between a tripeptide and its mirror (e.g., DAG and GAD are counted as the same) and each tripeptide contained in a 7-mer is counted only once (e.g., the count on AGA is incremented only once, although it is contained twice in the 7-mer). So, an observed 7-mer AGAGADR contributes a count for the four tripeptides AGA,GAG,DAG and ADR. The main reason for recording 3-mers are problems related to sparse counts that would result from recording the 20 7 possible 7-mers (Vendruscolo et. al., 2001) . In contrast there are only 4200 (20 3 , minus duplicate mirrors)
tripeptides. Finally, the data corresponding to the third stage contains two seven-peptides, 'XRGFRAA' in muscle and 'KTXXARX' in skin where one or more amino-acids, denoted by an 'X', are not identified. We consider the four tripeptides identified in the first one and discard counts for the second seven-peptide.
The data reports counts for all observed tripeptide-tissue pairs over 3 consecutive stages.
For the analysis, we excluded tripeptide-tissue pairs for which the cumulative count over all three stages was below 6, leaving n = 2763 distinct pairs. Table 1 illustrates the data format
by showing 6 rows of the data file.
[ Table 1 about here.] Figure 4 shows the parallel coordinates plot of raw data for these tripeptides-tissue pairs.
The desired inference is to identify tripeptide-tissue pairs with an increasing pattern across the three stages, i.e., to mark lines in the figure that show a clear increasing trend from first to third stage. Some lines in Figure 4 can be clearly classified as increasing, without reference to any probability model. But for many lines the classification is not obvious. The purpose of the proposed model-based approach is to define where to draw the line to define a significant increase.
Model

A Semi-parametric Mixture of Poisson Model
We use N i = (N i1 , N i2 , N i3 ) to denote the observed counts for tripeptide-tissue pair i across the three stages, for pairs i = 1, . . . , n. We cast the desired selection of tissue-specific tripeptides as inference about an increasing trend of mean counts in a probability model for the observed data N i . Kolonin et. al. (2006) Figure 4b . Although the data shows a marked difference in slopes from stages 1 to 2 versus from stages 2 to 3, the parametric model forces one common slope. This is a concern when the imputed overall slope is positive, e.g., the pair marked by A in the Figure 4b . Outliers like pair A in Figure 4b can inappropriately drive the inference. Taking advantage of the larger sample size, the semiparametric nature of the model that we propose can mitigate this problem. Finally, in Ji et. al. tripeptides are reported based on statistical significance, formalized as the posterior probability of the overall slope being greater than zero. We will propose an approach that also takes into account the size of the overall slope and is more suitable to incorporate biological significance.
In summary, the choice of an appropriate probability model is driven by the following considerations. First, we wish to limit the impact of specific parametric modeling choices on the inference about monotonicity of the mean counts. The experiment is designed to enlarge in subsequent stages any elevated counts that are due to preferential binding of a peptide to a particular tissue. In contrast, randomly high counts would not be enlarged in later counts. In other words, monotonicity of mean counts is equivalent to preferential binding.
This equivalence is central to the experiment. Therefore it is important that inference on monotonicity not be driven by outliers or arbitrary parametric forms. The large number of recorded pairs in the human data allows us to use a semi-parametric approach that reduces dependence on a specific parametric model. Second, we will later build on the probability model to define a formal decision problem for the selection of a final list of tripeptide-tissue pairs. For this, and for a simulation study to validate the model, we have to rely on efficient and fast computations.
These two competing desiderata lead us to consider a semi-parametric mixture model.
We will use a mixture of parametric Poisson models, with a nonparametric prior on the mixing measure. Under the Bayesian paradigm, nonparametric priors refer to probability models on probability distributions. In particular, we will use a Dirichlet process (DP)
prior for the random mixing measure in the mixture of Poisson model. We will later discuss details of the DP prior. The non-parametric prior on the mixing measure greatly generalizes the underlying parametric model, in much the same way as a mixture of independent normal kernels can approximate arbitrary multivariate distributions in kernel density estimates. Similar semi-parametric mixture models have successfully been applied for Bayesian inference in a variety of other applications, including mixed effects models, for example in Müller and Rosner (1997) , Mukhopadhyay and Gelfand (1997) or Kleinman and Ibrahim (1998) , case-control studies in Mukherjee et. al. (2007) , or point processes in Kottas and Behseta (2010) . The special case of binary outcomes has been discussed, among others, by Basu and Mukhopadhyay (2000) .
We start with a sampling model for N i conditional on assumed mean counts across stages for the peptide-tissue combination i. Conditional on the mean counts, we assume independent
Poisson sampling. In anticipation of the final inference goal we parameterize the mean counts
, allowing us to describe increasing mean counts by the simple event 1 <
for i = 1, . . . n. Model (1) implies independence of the counts across i, and dependence across stages k = 1, 2, 3. The dependence across stages is induced by the common base-line random effect µ i . The sampling model includes different Poisson means for each stage, in contrast to the model proposed by Ji et al. (2007) . The parameter µ i can be thought as the expected count mean of the pair i across the three stages if we were not enriching at every stage.
We extend (1) to the desired semi-parametric mixture model by assuming a non-parametric prior for a random effects distribution for
) denote a bivariate random probability measure. We discuss the probability model for G below. A parametric random effects distribution for µ i keeps computation simple.
The parametrization of the Gamma distribution is chosen such that E(X) = a/b for X ∼ Ga(a, b). Choosing a prior for the random probability measure G requires a nonparametric prior. The most commonly used model is the DP prior (Ferguson, 1973; Antoniak, 1974) . We write G ∼ DP (α, G 0 ) for a DP prior on the random probability measure G. The DP prior is indexed with two parameters, a total mass parameter α and a base measure G 0 . The total mass parameter is a precision parameter, and the base measure defines the prior expectation,
See, for example MacEachern and Müller (1998 ), Walker et. al. (1999 ), and Müller et. al. (2004 for recent reviews of the DP prior, including posterior inference for DP mixtures similar to the model used here. We assume
The independence of β and δ in the base measure G 0 (β, δ) simplifies posterior inference.
It does not reflect any prior information, and does not exclude dependence of the random effects distribution G(·). The non-parametric prior for G allows us to learn about possible correlations between β i and δ i , thus inducing additional correlations between round 2 and round 3 counts, if indicated by the data. The model is completed with a prior on the
Later, in the simulation and the data analysis we will fix the hyperparameters for the total mass parameter as a α = 5, b α = 0.5. In general, the specification of the total mass parameter in a DP prior model requires care because posterior inference can be critically sensitive with respect to this prior choice. However, this sensitivity arises mainly in inference about the implied clustering of experimental units, tripeptide-tissue pairs in our case. We will not interpret inference about the implied random partition in our analysis, thus reducing concerns about posterior sensitivity. An alternative approach to fix the prior for α is discussed, for example, in Dorazioet. al. (2008) .
Finally, a natural variation of the model could include µ i with (β i , δ i ) and use a similar DP mixture, now for the triple (µ i , β i , δ i ). We use the parametric model for µ i , for reasons of simplicity, and because the main inference goals relate to (β i , δ i ) only.
Posterior Simulation
The model (1) 
The rule d * can be justified in terms of the false discovery rate (FDR) control (Newton, 2004) or, alternatively, as an optimal Bayes rule. To define an optimal rule we need to augment the probability model to a decision problem by introducing a utility function. Let θ and y generically denote all unknown parameters and all observable data. A utility function u(d, θ, y) formalizes relative preferences for decision under hypothetical outcomes y and under an assumed truth θ. For example, a utility function could be
i.e., a linear combination of the number of true positive selections d i and true negatives. In this case the utility function involves the data y only indirectly through the decisions d. For a given probability model, data and utility function, the optimal Bayes rule is defined as the rule that maximizes u in expectation over all not observed variables, and conditional on all observed variables. In our case,
It can be shown that d * arises as Bayes rule under several utility functions that trade off false positive and false negative counts, including the utility in (6) and others. See, for example, Müller et. al. (2007) , for a discussion. 
Similarly, the posterior expected false negative rate (FNR) can be computed as E(FNR |
. It is easily seen that the pairs selected by d i ⋆ report the largest list for a given value of posterior expected FDR. Ji et. al. (2007) selected the pairs with increasing means across the three stages according to the FDR-based criterion (5) where p i is the probability of (common) positive slope (across the stages 1 and 2, and 2 and 3) according to their model. As can be seen from (6), the control of posterior expected FDR implies a criterion that does not take into account the size of the increase. In other words, a shortcoming of the rule d * is that it implicitly weights all true positives equally. However, it would be desirable to rank their selection strength. To achieve this, we will use a utility function that gives weights to the pairs proportional to the relative increment from the first to the third stages (i.e. δ i .) As alternative to (6) we consider the utility function
where w = (w 1 , · · · , w n ) is a vector of weights. We use
c > 0 represents the cost of declaring that a pair has increasing means; and k > 0 is such that kw i is the cost of falsely not reporting pair i when the corresponding (unknown true) means are actually increasing.
Let m i = E(w i | N). Straightforward algebra shows that the optimal rule is
With a Monte Carlo posterior sample (β
and then make the decision d i B .
A Simulation Study
We carried out a simulation study to validate the proposed approach. We generated n = 2000 observations of the model described in (1) through (4), except that the random probability measure G is replaced by a gamma distribution with fixed parameters
We set the hyper-parameters such that the expected value of µ i and its variance are small and, besides, β i and δ i have both mean 8 and variances 30 and 120 respectively. The motivation for this choice is that µ i is interpreted as the mean of the counts through the three stages of the pair i if there were no enrichment. Since, initially, the library contains a small amount of the particular tripeptide related with the pair i among the large number of different tripeptides, we expect µ i to be small. The parameters β i and δ i represent the fold increase in mean counts from the first stage to the second and third stages, respectively, due to the library enrichment. We allow these last parameters large variances. The gamma parameters were set to s 
The hyper-parameters of the model described in (1) through (4) were chosen taking into account the same considerations and set to s µ = 0.05, a tµ = 3, b tµ = 1/2, s β = s δ = 5/3, a t β = a t δ = 6, b t β = b t δ = 25, a α = 5 and b α = 0.5. Saving every 10 th iteration after a 10,000 iteration burn-in, a Monte Carlo posterior sample of size M = 5, 000 was saved.
Using the FDR criterion,we selected the pairs such that, under the assumptions of our model, the expected false discovery rate was 0.2. The implied expected FNR was 0.117.
Under this rule, we reported 715 pairs for increasing means across the three stages. Of these 578 truly did have increasing mean counts in the simulation truth, i.e., the observed FDR and FNR were 0.192 and 0.113, respectively.
Next we considered selection with respect to the alternative utility function (8) Our model is a particular case of a DP mixture model. Like in any density estimation model we can evaluate the posterior mean estimated distribution as the predictive distribution for a future draw. Specifically, in model (2) we find
i.e., the predictive distribution for a future pair (β n+1 , δ n+1 ) is identical with the posterior mean G of the unknown random effects distribution G. Comparing G with the simulation truth we find that the estimated distribution matches the true gamma distributions quite closely. See the SWM Figure 1 .
For comparison we analyze the same data using the approach proposed in Ji et. al. (2007) .
Their model differs in two important ways from the proposed model (1) through (5). First, they assume a simplified sampling model, in our notation, with
We use a superindex . In summary, the parametric model reports high posterior probability of increasing mean counts even when there is no evidence in the data.
Finally, we compare the proposed semiparametric model with an empirical Bayes (EB) parametric version of it. We consider an alternative parametric model that replaces the random probability measure G in (3) by the parametric model G 0 and we fix t µ , t β and t δ in (4) and assumes µ i ∼ Ga(s µ , s µ t µ ), β i ∼ Ga(s β , s β t β ) and δ i ∼ Ga(s δ , s δ t δ ). 
Results
We present the analysis of the human phage display data under the proposed method. We fix the hyper-parameters as in the simulation study. In particular, the hyperprior choices imply the following marginal means and variances. The parameter µ i is interpreted as the expected counts if there were no enrichment of the library of tripeptides at every stage. We assume that most of the phage counts are small in the initial state. Therefore, we set the expected value for the first stage counts µ i to 0.25 and its variance to 2.56. We do not assume any knowledge of the mean increment between the first and the second stage (i.e., β i ) and between the first and the third stage (i.e., δ i ). We center these values around a mean of 5 and allow for a large variance of 25.
We saved a Monte Carlo posterior sample of size M = 5, 000, saving the values of the imputed parameters every ten iterations after a burn-in of 10, 000 iterations. Similar to the simulation study, we evaluate convergence diagnostics to ensure practical convergence of the MCMC simulation. We found no evidence for a practical lack of convergence. We explore the fit of the proposed model and hierarchical shrinkage by plotting the observed tritpeptidetissue counts versus the posterior expected means
The plot (shown in SWM Figure 3abc) shows the usual hierarchical shrinkage of the mean counts corresponding to smaller counts towards the overall mean.
A scatter plot of β i = E(β i | N) and δ i = E(δ i | N) (shown in SWM Figure 3d ) includes many points that are close to either the vertical line through 1, indicating no enrichment from the first to the second stages, or close to the identity line, indicating no enrichment from the second to the third stages. This complicates inference by making the decision to report many pairs very sensitive to details of the parametric model. Finally, Figure 3 shows the posterior estimated random effects distribution G = E (G | N) . This shape of G would be very difficult to re-create in a parametric model without overfitting. In particular, the multimodal nature of G is intriguing. The secondary modes might allow interesting biologic interpretation.
[ Figure 3 about here.] Table 2 shows the 31 pairs with highest m i , i.e, the pairs chosen by d B , with a threshold of c/(k + 1) = 9. We notice that there are some pairs, such as the tripeptide GRM in fat tissue, that present a small posterior probability p i of increasing means but that are selected under d B due to a large m i . Of the top 31 tripeptides all but two (RPR and GWS in bone marrow)
have been previously identified through dataset analysis with independent statistical methods in Staquicini et. al. (2011) . Tripeptides progressively enriched in the prostate have not been included in the previously published data because this tissue was excluded from analysis for technical considerations. Two tripeptides (QGS and QGW), identified here as enriched in the bone marrow, were also reported enriched in the same tissue in Staquicini et. al.(2011) .
In the same work, the majority of progressively enriched tripeptides (19, including prostateenriched) were identified as "shared" (enriched in more than one tissue), and, interestingly, four progressively enriched tripeptides were identified as enriched in different tissues. Figure 4 is an example in which there is no statistical evidence of an increasing pattern (since β i < 1). Nevertheless, the decision rule (9) tends to pick this pair due to its large count observed at the third stage.
Although inference on the implied clusters is not a focus of this study, the DP mixture model allows such inference. For the n = 2763 peptide-tissue pairs we find a posterior mean of 35.8 clusters.
Discussion
We have proposed semi-parametric model-based statistical inference for high dimensional count data arising from phage experiments with parallel biopanning. The probability model is extended to a decision problem by adding a utility function for the choice of reported tripeptide-tissue pairs.
Previously, Ji et. al. (2007) introduced a model for the analysis of phage experiment mouse data. Analogous to their model, ours accounts for the correlation that exists between the different stages and detects the tripeptides that tend to bind with a specific tissue. Since there is just one observation across the three stages for every tripeptide-tissue pair, the use of a hierarchical model to implement borrowing of strength across all pairs is critical.
The proposed model allows a non-linear mean structure across the three stages, and it includes a non-parametric random effects distribution to accomodate outliers, taking advantage of the large data set. The random effects µ i , β i , and δ i have an easy interpretation:
µ i is the mean count of the tripeptide-tissue pair i if there were no enrichment of the tripeptide library at every stage, while β i and δ i are the fold increment at the second and third stages, respectively, due to this enrichment. This parametrization allows for an easy description of the target event of increasing mean counts through the three stages.
The proposed model includes random baseline means µ i to allow a variation of the amount of tripeptides in the original phage display peptide library. It is important to include such random effects. Large counts at the third stage can be explained by either preferential binding of a certain tripeptide, or simply by high random counts in the original library. The inclusion of the random baseline means allows us to differentiate these two cases.
In selecting the tripeptide-tissue pairs with increasing means across the three stages, we face a massive multiplicity problem. We use a decision theoretic setup with a utility function that takes into consideration statistical significance as well as biological significance such as the size of the mean increase through the three stages.
The nonparametric nature of our model exploits the large sample size to learn about the distribution of mean patterns across the population of tripeptide-tissue pairs. The semiparametric model implements multiple shrinkage by implicitely defining clusters of pairs with similar mean pattern. We demonstrated how the semi-parametric model avoids inappropriate overall shrinkage as it would be implied by a comparable parametric model.
Among the remaining limitations of the model is that it fails to allow that different tissues can have different selection behaviors. For example, there may be a tissue that absorbs more tripeptides, or that is associated with different variances of the counts. The problem is mitigated by including the base-line mean count µ i , but the model could be further improved by a priori incorporating a correlation structure of pairs sharing the same tissue. This could be achieved, for example, by adding an additional hierarchical layer in the model. Table and Figures referenced in Sections 3, 5 and 6 are available with this paper at the Biometrics website on Wiley Online Library. The R and C code, and necessary (simulated and real) data to reproduce the analysis in this paper are located in the folder "analysis.zip".
Supplementary Materials
This folder is also available at the same website. . Marked in black are the 62 selected pairs using the optimal rule (9) with a threshold value of 7. Counts are jittered for visual purposes. 
